Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 2/20 | 0.59 |
| ▸ | NPY4R | P50391 | 6/20 | 0.56 |
| ▸ | NPY1R | P25929 | 4/20 | 0.56 |
| ▸ | NPY2R | P49146 | 4/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | KDM5A | P29375 | 1/20 | 0.55 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.53 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13807691 | 0.96 | EPHA2 (0.57) | EPHA2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13807701 | 0.93 | EPHA2 (0.57) | EPHA2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13807693 | 0.91 | NTSR2 (0.56) | EPHA2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL10592955 | 0.88 | NTSR2 (0.64) | NPY4RNPY1RNPY2RNPY5RNTSR1 | |
| SCHEMBL31257023 | 0.86 | EPHA2 (0.57) | EPHA2NTSR1NTSR2SORT1CALCRL | |
| SCHEMBL13816930 | 0.85 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30389216 | 0.85 | EPHA2 (0.60) | EPHA2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL9807256 | 0.85 | EPHA2 (0.59) | EPHA2KDM1AMAOBKDM5AKDM1B | |
| SCHEMBL8876493 | 0.84 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5RNTSR1 | |
| SCHEMBL29770298 | 0.84 | NPY4R (0.57) | EPHA2NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078092-A1 | Cell permeable conjugates of peptides for inhibition of protein kinases | CUREGENICS LTD. (IL) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078092-A1 | Cell permeable conjugates of peptides for inhibition of protein kinases | MAP3K20, MAP3K19, MAP4K2 | EPHA2 557/4885NPY4R 4505/4885NPY1R 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.